| scholarly article | Q13442814 |
| P50 | author | Kelly D Farwell Hagman | Q56484385 |
| Zoe Powis | Q57059650 | ||
| Layla Shahmirzadi | Q85891866 | ||
| Nancy Niguidula | Q92270913 | ||
| Christina Alamillo | Q92270916 | ||
| Julie S Cohen | Q92270921 | ||
| P2093 | author name string | Zöe Powis | |
| Kelly D Farwell Hagman | |||
| Julie S Cohen | |||
| Christina Alamillo | |||
| Layla Shahmirzadi Mowlavi | |||
| Nancy Niguidula | |||
| P2860 | cites work | Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease | Q28301461 |
| ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing | Q29616235 | ||
| Exploring the utility of whole-exome sequencing as a diagnostic tool in a child with atypical episodic muscle weakness | Q30572046 | ||
| Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. | Q33600262 | ||
| Clinical whole-exome sequencing for the diagnosis of mendelian disorders | Q34413680 | ||
| Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics | Q34544874 | ||
| Clinical exome sequencing for genetic identification of rare Mendelian disorders | Q34782655 | ||
| Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders | Q34866575 | ||
| Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia | Q35073865 | ||
| Molecular findings among patients referred for clinical whole-exome sequencing | Q35078373 | ||
| Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center's Experience. | Q35910407 | ||
| Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth | Q36592140 | ||
| Reducing the Cost of the Diagnostic Odyssey in Early Onset Epileptic Encephalopathies. | Q36924136 | ||
| Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care | Q37316405 | ||
| Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations | Q37529593 | ||
| Candidate-gene criteria for clinical reporting: diagnostic exome sequencing identifies altered candidate genes among 8% of patients with undiagnosed diseases. | Q37637598 | ||
| GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia | Q37723860 | ||
| Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. | Q38263926 | ||
| A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology | Q38883296 | ||
| Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. | Q38912161 | ||
| Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. | Q38997779 | ||
| Clinical application of whole-exome sequencing across clinical indications | Q41075733 | ||
| High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders | Q41927928 | ||
| Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions. | Q47681796 | ||
| Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: the China experience | Q47725541 | ||
| Use of Exome Sequencing for Infants in Intensive Care Units: Ascertainment of Severe Single-Gene Disorders and Effect on Medical Management. | Q50260153 | ||
| Clinical whole exome sequencing in child neurology practice. | Q50305196 | ||
| The usefulness of whole-exome sequencing in routine clinical practice. | Q50657606 | ||
| A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases | Q57536768 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1068-1078 | |
| P577 | publication date | 2018-10-14 | |
| P1433 | published in | Molecular genetics & genomic medicine | Q27724709 |
| P1476 | title | Clinical whole-exome sequencing results impact medical management | |
| P478 | volume | 6 |
| Q90438987 | A pediatric perspective on genomics and prevention in the twenty-first century |
| Q99609303 | A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis |
| Q90003673 | Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS) |
| Q91671031 | miRNA Genetic Variants Alter Their Secondary Structure and Expression in Patients With RASopathies Syndromes |
Search more.